• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For Stryker (SYK) Could Change Following Its Mixed-Reality Hip Surgery Milestone

    Simply Wall St·09/02/2026 11:18:15
    Listen to the news
    • Stryker recently completed the first hip arthroscopy using its FDA De Novo–authorized SportSuite Vision software on Apple Vision Pro, bringing arthroscopic video, HipCheck, HipMap and CT imaging into a single augmented reality field of view in the operating room.
    • This milestone highlights how mixed reality can consolidate multiple data sources directly into a surgeon’s line of sight, potentially improving ergonomics and operating room workflow efficiency.
    • We’ll now examine how the FDA De Novo authorization for SportSuite Vision may influence Stryker’s investment narrative and digital-health positioning.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Stryker Investment Narrative Recap

    To own Stryker, you generally need to believe in long term procedure growth, the value of its innovation engine and its ability to convert that into durable earnings. The SportSuite Vision FDA De Novo authorization and first clinical use reinforce Stryker’s push into digital surgery, but they do not materially change the near term focus on resolving supply chain issues and managing cost pressures, which still look like the key short term swing factors and risks.

    Among recent announcements, the launch of Mako RPS for total knee procedures is especially relevant, because it underscores how SportSuite Vision fits into a broader push to deepen Stryker’s presence in tech enabled, minimally invasive orthopedics. Together, these offerings expand Stryker’s digital and robotics footprint around the operating room, tying into the core catalysts of product innovation, procedure mix shift and deeper integration with high volume surgical settings.

    But investors should also be mindful that prolonged regulatory bottlenecks and higher compliance costs in key markets could still...

    Read the full narrative on Stryker (it's free!)

    Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029. This requires 8.9% yearly revenue growth and a $3.2 billion earnings increase from $3.3 billion today.

    Uncover how Stryker's forecasts yield a $386.80 fair value, a 22% upside to its current price.

    Exploring Other Perspectives

    SYK 1-Year Stock Price Chart
    SYK 1-Year Stock Price Chart

    Seven members of the Simply Wall St Community currently see Stryker’s fair value between US$331 and US$426, showing a wide spread of opinions. Against that backdrop, the mixed reality and robotics push highlighted above could matter a lot for how you think about Stryker’s long term earnings power and resilience.

    Explore 7 other fair value estimates on Stryker - why the stock might be worth as much as 34% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.